Elekta (Sweden) and Electronic Registry Systems (ERS) are the Leading Players in the Cancer Registry Software Market
The cancer patient registry software market is projected to reach USD 91 million by 2024 from USD 56 million in 2019, at a CAGR of 10.4% during the forecast period. Growth in this market is majorly driven by the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance. On the other hand, factors such as privacy and data security-related concerns may restrain the growth of this market to a certain extent.
The key players operating in this market are Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US). Acquisitions and collaborations were the key growth strategies adopted by market players from 2016 to 2018. Some of the leading players that adopted these strategies include Elekta (Sweden) and McKesson Corporation (US).
To know about the assumptions considered for the study download the pdf brochure
Elekta is one of the leading players in the cancer patient registry software market. Its key expertise lies in precision radiation medicine. The company has a strong product portfolio, ranging from clinical software to medical equipment for cancer care and the treatment of brain disorders. Elekta provides cost-effective and high-quality cancer care services and software to its customers. It focuses on inorganic growth strategies to maintain its strong position in the market. For instance, the company entered into a collaboration with IBM Watson Health to incorporate Watson for Oncology with Elekta’s cancer care solutions. The company also invests heavily in R&D activities to introduce novel products and improve its existing product line. It invested USD 8.9 billion, USD 8.8 billion, and USD 9.0 billion in R&D in 2016, 2017, and 2018, respectively. The company caters to leading hospitals, clinics, and government organizations with an aim to provide effective cancer care.
Electronic Registry Systems (ERS) is another leading player in the cancer patient registry software market. The long-term presence of the company in the market and its significant presence across major countries are the major factors that provide ERS with a competitive edge over other players. The company’s cloud-based CRStar technology helps in curtailing ongoing costs and minimizes start-up time for hospitals and healthcare facilities. The end users of these solutions include hospitals, physicians, cancer program administrators, and oncology data managers, among others.
Onco, Inc. is one of the major players operating in the cancer patient registry software market. The company focuses on providing solutions to support cancer registry data management. The OncoLog cancer registry provided by the company helps in diagnosing, documenting, and analyzing cancer treatment patterns, complications, and outcomes. The company focuses on offering exceptional customer support, technological infrastructure, and consulting services to its customers. The cancer registry software provided by Onco is well accepted in the market as it adheres to regulatory guidelines and quality assurance reporting requirements.
Related Reports:
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
